Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT 주식 리포트

시가총액: US$919.8m

Phathom Pharmaceuticals 대차대조표 건전성

재무 건전성 기준 점검 1/6

Phathom Pharmaceuticals 의 총 주주 지분은 $-337.0M 이고 총 부채는 $544.6M, 이는 부채 대 자기자본 비율을 -161.6% 로 가져옵니다. 총자산과 총부채는 각각 $305.1M 및 $642.1M 입니다.

핵심 정보

-161.62%

부채/자본 비율

US$544.59m

부채

이자보상배율n/a
현금US$180.90m
자본-US$336.95m
총부채US$642.08m
총자산US$305.12m

최근 재무 건전성 업데이트

업데이트 없음

Recent updates

내러티브 업데이트 • May 02

PHAT: Regulatory Exclusivity Outlook Will Support Anticipated 2026 Profitability Timeline

Narrative update on Phathom Pharmaceuticals The updated analyst price target for Phathom Pharmaceuticals has moved to $23.70, with analysts pointing to refreshed models that factor in revised revenue growth and profit margin assumptions, an adjusted future P/E, and recent research highlighting expectations around potential profitability timing, regulatory exclusivity and consumer marketing uncertainty. Analyst Commentary Recent Street research on Phathom Pharmaceuticals highlights a mix of optimism around the path to profitability and caution around long term exclusivity and commercial execution.
내러티브 업데이트 • Apr 15

PHAT: Regulatory Exclusivity Outlook Supports Path To 2026 Profitability

Phathom Pharmaceuticals' fair value estimate has shifted from $22.90 to $23.70 as analysts factor in higher long term profit margin assumptions, recent price target increases to $25 and $13, and updated views on regulatory exclusivity and potential generic competition after 2032. Analyst Commentary Recent Street research provides a mixed but useful view of how expectations are settling around Phathom Pharmaceuticals' execution and long term earnings power.
내러티브 업데이트 • Apr 01

PHAT: Profitability In 2026 Will Challenge Post 2032 Generic Overhang

Narrative Update The analyst price target for Phathom Pharmaceuticals is now aligned with a fair value estimate of about $13.62, with analysts pointing to updated models following Q4 results, refined assumptions around revenue growth, profit margins and future P/E, as well as recent target increases to $13 and $25 that reflect views on regulatory exclusivity and the path toward potential profitability in early Q3 2026. Analyst Commentary Recent Street research around Phathom Pharmaceuticals has centered on updated models following Q4 results, with analysts adjusting their targets to reflect revised assumptions on regulatory exclusivity, marketing execution and the timing of potential profitability.
내러티브 업데이트 • Mar 18

PHAT: Profitability In 2026 Will Test Post 2032 Generic Assumptions

Narrative Update on Phathom Pharmaceuticals Analysts have raised Phathom Pharmaceuticals' price target to a range that now reaches up to $25, up from prior targets as low as $12, citing updated models after the Q4 earnings beat, revised assumptions around regulatory exclusivity and generic entry after 2032, and expectations for the company to work toward profitability in early Q3 2026. Analyst Commentary Analysts reviewing Phathom Pharmaceuticals after its Q4 earnings beat have adjusted their models and price targets, but with differing levels of enthusiasm.
내러티브 업데이트 • Mar 04

PHAT: Profitability Expected In 2026 Could Reframe Long Term Generic Risk

Narrative Update on Phathom Pharmaceuticals The analyst price target underpinning our fair value view on Phathom Pharmaceuticals has shifted from $12 to $13. This reflects updated models that factor in the recent Q4 earnings beat, revised assumptions on regulatory exclusivity and potential generic entry after 2032, and expectations around the company's path toward potential profitability in early Q3 2026.
내러티브 업데이트 • Feb 18

PHAT: Follow On Equity Raise Will Support Path To 2026 Profitability

Analysts have kept their $22.90 price target for Phathom Pharmaceuticals broadly unchanged, citing only marginal adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions in their valuation work. What's in the News Phathom Pharmaceuticals completed a follow on equity offering totaling approximately US$130.0 million.
내러티브 업데이트 • Feb 04

PHAT: Equity Raise And 2026 Profitability Outlook Will Support Further Upside

Analysts have maintained their overall view on Phathom Pharmaceuticals, making only modest adjustments to assumptions such as revenue growth, profit margin, and future P/E. Taken together, these inputs support an unchanged fair value estimate of US$22.90 per share.
내러티브 업데이트 • Jan 20

PHAT: Equity Raise And 2025 Profitability Outlook Will Support Further Upside

Analysts have modestly adjusted their price assumptions for Phathom Pharmaceuticals, and the implied fair value remains at $22.90. Small changes to revenue growth, profit margin expectations, and future P/E assumptions have effectively offset one another.
Seeking Alpha • Jan 09

Phathom: Why I'm Not Buying The Dip (Yet)

Summary Phathom Pharmaceuticals (PHAT) remains a Hold as VOQUEZNA's commercial execution improves, but balance sheet leverage and dilution persist. Q4 prerelease shows VOQUEZNA revenue ramping (~15–17% Q/Q), with cost resets driving non-GAAP opex below restructuring targets. Equity raise of $130M at $16/share reduces near-term solvency risk but highlights ongoing obligations and ~11% dilution. Valuation remains stretched; PHAT is highly sensitive to execution, GTN stability, and post-2032 terminal value risk. Read the full article on Seeking Alpha
분석 기사 • Jan 08

Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%

Despite an already strong run, Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have been powering on, with a gain...
내러티브 업데이트 • Jan 06

PHAT: Late-Stage Gastrointestinal Trials And 2025 Guidance Will Drive Upside Momentum

Analysts have maintained their price target for Phathom Pharmaceuticals at US$22.90. This reflects only minor adjustments in key model inputs, including the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any change in their overall view.
내러티브 업데이트 • Dec 16

PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum

Analysts have slightly trimmed their price target on Phathom Pharmaceuticals from approximately $23.13 to $22.90 per share, reflecting modestly higher long term growth and margin expectations, offset by a lower projected valuation multiple. What's in the News First patient dosed in the Phase 2 pHalcon EoE-201 trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with topline results expected in 2027 (company announcement) Additional analyses from the pivotal Phase 3 pHalcon NERD-301 trial of VOQUEZNA in Non Erosive Reflux Disease published in the American Journal of Gastroenterology, highlighting benefits for nighttime GERD symptoms (company announcement, medical journal) Full year 2025 revenue guidance updated to a range of 170 million dollars to 175 million dollars, indicating expectations for continued commercial ramp (company guidance) Sanjeev Narula appointed Chief Financial and Business Officer, bringing extensive large cap pharma and transaction experience from prior CFO roles at Intra Cellular Therapies, Viatris, and Pfizer divisions (company announcement) Valuation Changes Fair Value Estimate has edged down slightly from approximately $23.13 to $22.90 per share.
내러티브 업데이트 • Dec 01

PHAT: Clinical Pipeline Advances And Index Inclusion Will Support Upside Momentum

Analysts have maintained their price target for Phathom Pharmaceuticals at $23.13 per share, citing consistent revenue growth expectations and stable profit margin forecasts as the basis for leaving their projections unchanged. What's in the News First patient dosed in Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with primary and secondary results expected in 2027 (Key Developments) Updated full-year 2025 revenue guidance to a range of $170 million to $175 million (Key Developments) New data from Phase 3 pHalcon-NERD-301 trial for VOQUEZNA published, showing improvements in nocturnal symptoms for Non-Erosive Reflux Disease and highlighting safety considerations (Key Developments) Appointment of Sanjeev Narula as Chief Financial and Business Officer, bringing extensive financial and strategic experience from leadership roles at Intra-Cellular Therapies, Viatris, and Pfizer (Key Developments) Added to S&P Pharmaceuticals Select Industry Index (Key Developments) Valuation Changes Consensus Analyst Price Target remains steady at $23.13 per share with no change from previous estimates.
내러티브 업데이트 • Nov 17

PHAT: Early Clinical Trial Progress Will Drive Shares Higher

Analysts have maintained their fair value price target for Phathom Pharmaceuticals at $23.13 per share. They cite only marginal adjustments to growth estimates and risk assumptions.
내러티브 업데이트 • Nov 01

PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead

Analysts have raised their price target for Phathom Pharmaceuticals from $21.38 to $23.13. They cite an improved profit margin outlook, despite more conservative revenue growth projections.
내러티브 업데이트 • Sep 04

Gastroenterology Focus Will Unlock Enduring Market Potential

Analysts reaffirmed their price target for Phathom Pharmaceuticals at $21.38, citing 10-year market exclusivity for Voquezna, diminished generic risk, and robust launch metrics as drivers of renewed confidence and market opportunity. Analyst Commentary FDA granted 10-year market exclusivity for Voquezna tablets under GAIN, extending exclusivity to May 2032 with a likely pediatric extension through late 2032.
분석 기사 • Jul 19

Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge

Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have retraced a considerable 27% in the last month, reversing a...
분석 기사 • Jun 02

Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump

Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shareholders are no doubt pleased to see that the share price has bounced...
User avatar
새로운 내러티브 • May 09

Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity

Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.
분석 기사 • Apr 18

Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge

Unfortunately for some shareholders, the Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) share price has dived 27% in the...
Seeking Alpha • Dec 11

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Summary Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior, spiking post-Q2 earnings and plummeting post-Q3 earnings. Despite significant prescription growth and revenue increases, Q3 showed slower progress, raising concerns about the drug's market uptake and second-line approval status. High SG&A expenses and limited cash runway pose financial risks, alongside unclear reasons for stagnant sales despite label expansions. I exited my PHAT position in August and have no plans to reinvest due to these uncertainties and financial concerns. Read the full article on Seeking Alpha
Seeking Alpha • Sep 03

Following Up On Phathom Pharmaceuticals

Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product VOQUENZA is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUENZA have at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Jun 26

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Summary Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. The delays in launching Voquenza have been frustrating, but now the company is conducting a full launch and may secure a lucrative label expansion with an approval in non-erosive GERD next month. Read the full article on Seeking Alpha
Seeking Alpha • Mar 18

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Summary The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. A soon-to-be-initiated phase 3 study in 2024 is going to explore the use of Voquenza with "As Needed" dosing to treat Non-Erosive GERD patients. Voquenza may also be used to treat patients with another gastrointestinal disorder, such as eosinophilic esophagitis. A phase 2 study using this drug to treat this patient population is expected to be initiated in 2024. Read the full article on Seeking Alpha

재무 상태 분석

단기부채: PHAT 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: PHAT는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채/자본 비율 추이 및 분석

부채 수준: PHAT 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: PHAT는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.

대차대조표

현금 보유 기간 분석

과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.

안정적인 현금 활주로: PHAT 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: PHAT 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

건전한 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/22 19:52
종가2026/05/22 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Phathom Pharmaceuticals, Inc.는 15명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jenna DavidnerBarclays
null nullBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.